Intervention: Tetrafluoroborate
Trial phase: Phase 1 | Phase 2
SMILES: F[B-](F)(F)F
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: For cancer patients undergoing virus treatments, subjects will undergo [18F]BF4-PET/CT imaging at baseline before virus administration and at day 9 following virus treatment. Subjects will be screened by physician specialists within their clinics. Subjects who qualify for the study will return to the clinic within 30 days of screening, have a urine pregnancy test (if applicable) and will have catheters placed for i.v. drug administration. Vital signs will be obtained. All subjects will then receive a single i.v. bolus of [18F]BF4 for injection and PET/CT imaging will begin. Biopsies will be performed to confirm NIS expression in tissue of tumor regions showing uptake of [18F]BF4 in up to three myeloma patients when the site is accessible for biopsy.

BF4: Single IV dose of 9-11 mCi sodium [Fluorine-18] radiolabeled B4^F
Eligibility criteria:
Inclusion Criteria:

Four male and four female healthy volunteers, greater than 21 years of age.
Subjects must provide written informed consent.
Willingness to provide all biological specimens as required by the protocol

Exclusion Criteria:

Volunteers with any of the following are ineligible to enroll in this study:

Have currently clinically significant cancer, neurologic, hepatic, renal, pulmonary, metabolic, or endocrine disturbances, especially thyroid disease;

Current clinically significant cardiovascular disease. Clinically significant cardiovascular disease usually includes one or more of the following:

cardiac surgery or myocardial infarction within the last 6 months;
unstable angina;
coronary artery disease that required a change in medication within the last 3 months;
decompensated congestive heart failure;
significant cardiac arrhythmia or conduction disturbance, particularly those resulting in atrial or ventricular fibrillation, or causing syncope, near syncope, or other alterations in mental status;
severe mitral or aortic valvular disease;
uncontrolled high blood pressure;
congenital heart disease;
History of drug or alcohol abuse within the last year, or prior prolonged history of abuse;
Clinically significant infectious disease, including AIDS or HIV infection or previous positive test for hepatitis B, hepatitis C, HIV-1, or HIV-2;
Women of childbearing potential must not be pregnant (negative urine Human Chorionic Gonadotropin (β-HCG) at the time of screen) or lactating over the course of the study. A commercial urine dipstick test will be performed within 48 hours prior to injection of [18F]BF4 unless the screening urine pregnancy test falls within 48 hours of injection.
Volunteers who, in the opinion of the investigator, are otherwise unsuitable for a study of this type;
History of severe drug allergy or hypersensitivity; or
Volunteers who had received an investigational medication within the last 30 days or who have participated in a clinical trial with any experimental medication or radiopharmaceutical in the last 30 days. Additionally, the time between the last dose of the previous experimental medication and enrollment (completion of screening assessments) must be at least equal to 5 times the terminal half-life of the previous experimental medication.
Volunteers who are taking drugs with narrow therapeutic windows, such as theophylline, or warfarin, heparin and other anticoagulant therapies